$TVTX
Travere Therapeutics Inc

2023 Q4 Form 10-Q Financial Statement

#000143853323000048 Filed on November 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $45.06M $37.10M
YoY Change -19.35% -30.66%
Cost Of Revenue $4.564M $1.289M
YoY Change 164.12% -23.04%
Gross Profit $40.50M $35.81M
YoY Change -25.2% -30.9%
Gross Profit Margin 89.87% 96.53%
Selling, General & Admin $52.73M $67.80M
YoY Change -6.83% 17.88%
% of Gross Profit 130.22% 189.36%
Research & Development $58.75M $60.59M
YoY Change 1.67% 2.25%
% of Gross Profit 145.08% 169.22%
Depreciation & Amortization $11.85M $5.590M
YoY Change 27.43% -34.83%
% of Gross Profit 29.27% 15.61%
Operating Expenses $123.3M $128.4M
YoY Change 1.94% 9.95%
Operating Profit -$82.84M -$92.59M
YoY Change 23.92% 35.89%
Interest Expense $4.331M $2.800M
YoY Change 1877.63% -196.82%
% of Operating Profit
Other Income/Expense, Net $1.374M $3.356M
YoY Change 57.57% -343.72%
Pretax Income -$88.53M -$89.23M
YoY Change 34.62% 28.37%
Income Tax $68.00K $12.00K
% Of Pretax Income
Net Earnings -$90.17M $150.7M
YoY Change 36.99% -316.4%
Net Earnings / Revenue -200.12% 406.35%
Basic Earnings Per Share -$1.18 $1.97
Diluted Earnings Per Share -$1.17 $1.97
COMMON SHARES
Basic Shares Outstanding 75.15M shares 75.01M shares
Diluted Shares Outstanding 76.31M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $566.9M $356.9M
YoY Change 63.26% -20.36%
Cash & Equivalents $58.18M $144.2M
Short-Term Investments $508.7M $212.6M
Other Short-Term Assets $19.34M $16.20M
YoY Change 53.16% 89.5%
Inventory $9.410M $20.77M
Prepaid Expenses
Receivables $21.18M $14.60M
Other Receivables $0.00 $0.00
Total Short-Term Assets $616.8M $686.2M
YoY Change 26.79% 28.31%
LONG-TERM ASSETS
Property, Plant & Equipment $25.54M $7.996M
YoY Change 182.24% -16.33%
Goodwill $800.0K $800.0K
YoY Change -11.11% -11.11%
Intangibles $104.4M $106.9M
YoY Change -27.99% -28.48%
Long-Term Investments
YoY Change
Other Assets $42.16M $12.92M
YoY Change 281.11% 16.41%
Total Long-Term Assets $172.1M $146.6M
YoY Change -7.53% -23.39%
TOTAL ASSETS
Total Short-Term Assets $616.8M $686.2M
Total Long-Term Assets $172.1M $146.6M
Total Assets $788.9M $832.9M
YoY Change 17.3% 14.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $41.68M $24.74M
YoY Change 141.04% 76.56%
Accrued Expenses $123.9M $95.71M
YoY Change 29.41% 8.29%
Deferred Revenue $7.096M $8.959M
YoY Change -40.75% -21.29%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $177.9M $139.4M
YoY Change 25.14% 6.41%
LONG-TERM LIABILITIES
Long-Term Debt $377.3M $376.8M
YoY Change 0.46% 0.45%
Other Long-Term Liabilities $32.93M $8.381M
YoY Change 250.9% -9.92%
Total Long-Term Liabilities $410.2M $8.381M
YoY Change 4270.75% -9.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $177.9M $139.4M
Total Long-Term Liabilities $410.2M $8.381M
Total Liabilities $588.1M $553.1M
YoY Change -6.61% -11.58%
SHAREHOLDERS EQUITY
Retained Earnings -$1.126B -$1.035B
YoY Change 10.98% 9.18%
Common Stock $7.000K $7.000K
YoY Change 16.67% 16.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $200.8M $279.8M
YoY Change
Total Liabilities & Shareholders Equity $788.9M $832.9M
YoY Change 17.3% 14.68%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$90.17M $150.7M
YoY Change 36.99% -316.4%
Depreciation, Depletion And Amortization $11.85M $5.590M
YoY Change 27.43% -34.83%
Cash From Operating Activities -$70.47M -$59.14M
YoY Change 28.97% 49.63%
INVESTING ACTIVITIES
Capital Expenditures $5.529M $4.930M
YoY Change 31.74% -164.59%
Acquisitions
YoY Change
Other Investing Activities -$11.42M $138.3M
YoY Change -64.85% 680.54%
Cash From Investing Activities -$16.95M $133.3M
YoY Change -53.81% 1222.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 122.0K -630.0K
YoY Change -77.86% -127.66%
NET CHANGE
Cash From Operating Activities -70.47M -59.14M
Cash From Investing Activities -16.95M 133.3M
Cash From Financing Activities 122.0K -630.0K
Net Change In Cash -87.30M 73.55M
YoY Change -3.84% -370.72%
FREE CASH FLOW
Cash From Operating Activities -$70.47M -$59.14M
Capital Expenditures $5.529M $4.930M
Free Cash Flow -$76.00M -$64.07M
YoY Change 29.17% 100.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Inventory Net
InventoryNet
20773000 usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
110679000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-92585000 usd
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2829000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-8513000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-8156000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
335000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12471000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-287582000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-245582000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
155000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
250000 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64033759 shares
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-69656000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-69656000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73523620 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73523620 shares
CY2021 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006CumulativeEffectPeriodOfAdoptionMember
CY2022Q4 us-gaap Inventory Net
InventoryNet
4523000 usd
CY2023Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 usd
CY2022Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
2990000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
686230000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
486437000 usd
CY2023Q3 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
0 usd
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
48342000 usd
CY2023Q3 us-gaap Assets
Assets
832850000 usd
CY2022Q4 us-gaap Assets
Assets
672585000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
24736000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17290000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
95712000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
95742000 usd
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8959000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11976000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4782000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4433000 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5244000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5722000 usd
CY2023Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 usd
CY2022Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
7000000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
139433000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
142163000 usd
CY2023Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
376833000 usd
CY2022Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
375545000 usd
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4574000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
10931000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23863000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27510000 usd
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8381000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9385000 usd
CY2023Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
0 usd
CY2022Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
64200000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
553084000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
629734000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75111517 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75111517 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64290570 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64290570 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
7000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1318861000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1059975000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1035449000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1014223000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3653000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2907000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
279766000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
42851000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
832850000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
672585000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37095000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28075000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
100179000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80121000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1289000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1114000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6886000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3552000 usd
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
60590000 usd
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
57145000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
185244000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
169246000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
67801000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
52420000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
201954000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
140434000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
129680000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-82604000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5842000 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2101000 usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2821000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-586000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-7578000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6323000 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-287737000 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-245832000 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
266511000 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
33173000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21226000 usd
us-gaap Net Income Loss
NetIncomeLoss
-212659000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.31
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-3.91
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-3.86
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
3.62
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.52
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.34
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63604962 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63604962 shares
us-gaap Net Income Loss
NetIncomeLoss
-21226000 usd
us-gaap Net Income Loss
NetIncomeLoss
-212659000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-728000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
4083000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-18000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-3218000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21972000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-211794000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
116485000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
156713000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
8464000 usd
CY2023Q3 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
151000 usd
CY2022Q3 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
3408000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
418000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
362000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2596000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1211000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-69656000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
279766000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
100676000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
42851000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
302112000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
36273000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
28751000 usd
us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
3240000 usd
us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
4354000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3545000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2428000 usd
tvtx Pre Funded Common Stock Warrants Net Of Issuance Costs
PreFundedCommonStockWarrantsNetOfIssuanceCosts
1600000 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
24630000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-728000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
4083000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-18000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-3218000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21226000 usd
us-gaap Net Income Loss
NetIncomeLoss
-212659000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
279766000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
100676000 usd
us-gaap Net Income Loss
NetIncomeLoss
-21226000 usd
us-gaap Net Income Loss
NetIncomeLoss
-212659000 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
266511000 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
33173000 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-287737000 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-245832000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
29042000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14407000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
36102000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
28846000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5181000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-323000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-7578000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
634000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-5377000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3295000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4944000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
17027000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1247000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4402000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2593000 usd
tvtx Change In Lease Assets And Liabilities Net
ChangeInLeaseAssetsAndLiabilitiesNet
-738000 usd
tvtx Change In Lease Assets And Liabilities Net
ChangeInLeaseAssetsAndLiabilitiesNet
-738000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
7468000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-198000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3903000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
16008000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-10200000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-8898000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-479000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2119000 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-260984000 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-184142000 usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
51436000 usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
52491000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-131651000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
643000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
36086000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
24199000 usd
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-133448000 usd
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
4148000 usd
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
206174000 usd
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
72726000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4148000 usd
tvtx Payment Of Guaranteed Minimum Royalty
PaymentOfGuaranteedMinimumRoyalty
1575000 usd
tvtx Payment Of Guaranteed Minimum Royalty
PaymentOfGuaranteedMinimumRoyalty
1575000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
316250000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
9882000 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
211324000 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
24630000 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3240000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4354000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2258000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1529000 usd
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
219751000 usd
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
118897000 usd
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
-1123000 usd
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
-1875000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
218628000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
117022000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
750000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-3935000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
82556000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14416000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61688000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165753000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
144244000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
151337000 usd
us-gaap Nature Of Operations
NatureOfOperations
DESCRIPTION OF BUSINESS<div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Travere Therapeutics, Inc. (“we”, “our”, “us”, “Travere” and the “Company”) refers to Travere Therapeutics, Inc., a Delaware corporation, as well as its subsidiaries. Travere is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on identifying, developing and delivering life-changing therapies to people living with rare kidney and metabolic diseases. The Company regularly evaluates and, where appropriate, acts on opportunities to expand its product pipeline through licenses and acquisitions of products in areas that will serve patients with serious </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">unmet medical need</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and that the Company believes offer attractive growth characteristics.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#006ebf;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations - Sale of Bile Acid Product Portfolio</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On July 16, 2023, Travere entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Mirum Pharmaceuticals, Inc. ("Mirum Pharmaceuticals" or “Mirum”), pursuant to which Mirum agreed to purchase from Travere substantially all of the assets primarily related to Travere’s business of development, manufacture (including synthesis, formulation, finishing or packaging) and commercialization of Chenodal and Cholbam (also known as Kolbam, and together with Chenodal, the “Products”), collectively, the "bile acid business". On August 31, 2023, the Company and Mirum consummated the transactions contemplated by the Purchase Agreement (the “Closing”). In connection with the Closing, Mirum paid Travere an upfront cash payment of $210.0 million. Pursuant to the Purchase Agreement, after the Closing, Travere is eligible to receive up to $235.0 million upon the achievement of certain milestones based on specified amounts of annual net sales (tiered from $125.0 million to $500.0 million) of the Products. The Company has reflected the bile acid business as a discontinued operation in the unaudited Consolidated Financial Statements for all periods presented. See Note 18 for further discussion. </span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unless otherwise noted, amounts and disclosures throughout the Notes to the unaudited Consolidated Financial Statements relate to the Company's continuing operations.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Approved Products:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#006ebf;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FILSPARI® (sparsentan)</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 17, 2023, the U.S. Food and Drug Administration (the "FDA") granted accelerated approval of FILSPARI® (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally at UPCR ≥1.5 gram/gram. FILSPARI, a once-daily, oral medication is designed to selectively target two critical pathways (endothelin 1 and angiotensin-II) in the disease progression of IgAN. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#006ebf;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Thiola® and Thiola EC® (tiopronin tablets)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thiola® and Thiola EC® (tiopronin tablets) are approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical-Stage Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The continued approval of FILSPARI for IgAN may be contingent upon confirmation of a clinical benefit in the Company's Phase 3 clinical trial of sparsentan for the treatment of IgAN (the "PROTECT Study"). Topline results from the two-year confirmatory endpoints in the PROTECT Study were reported in September 2023 and are intended to support traditional approval of FILSPARI.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sparsentan remains a novel investigational product candidate which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis (FSGS) in the U.S. and Europe. The double-blind portion of the Phase 3 study of sparsentan for FSGS has recently concluded and, following release of the top-line data from the study which showed that the study did not meet its primary endpoint, the Company is conducting further analyses of the data and is engaging with regulators to explore a potential path forward toward a potential regulatory submission in FSGS.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pegtibatinase (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TVT-058) is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU). Pegtibatinase has been granted Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations by the FDA, as well as orphan drug designation in the United States and European Union. Pegtibatinase is currently being evaluated in the Phase 1/2 COMPOSE Study to assess its safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects in patients with classical HCU. In May 2023, the Company announced positive topline results from cohort 6 in the Phase 1/2 COMPOSE Study. The Company is preparing for the potential initiation of a pivotal Phase 3 clinical trial of pegtibatinase in patients with HCU by the end of 2023, subject to communications and feedback from the FDA and associated program assessments. The Company</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> acquired pegtibatinase as part of the November 2020 acquisition of Orphan Technologies Limited.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is a participant in a Cooperative Research and Development Agreement ("CRADA"), which forms a multi-stakeholder approach to pool resources with leading experts, and incorporate the patient perspective early in the therapeutic identification and development process. The Company is partnering with the National Institutes of Health’s National Center for Advancing Translational Sciences ("NCATS") and a leading patient advocacy organization, Alagille Syndrome Alliance, aimed at the identification of potential small molecule therapeutics for Alagille syndrome ("ALGS"). There are no treatment options currently approved for ALGS.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is party to a collaboration agreement with PharmaKrysto Limited and their early-stage cystinuria discovery program, whereby the Company is responsible for funding all research and development expenses for the pre-clinical activities associated with the cystinuria program.</span></div>
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1289000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1114000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6886000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3552000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7500000 usd
us-gaap Revenue Performance Obligation Description Of Timing
RevenuePerformanceObligationDescriptionOfTiming
For FILSPARI, sales are recognized upon delivery of the product to the specialty pharmacies. The Company receives payments from its FILSPARI sales based on terms that are generally 30 days from shipment of the product to the specialty pharmacy. For the Company's other products, product sales are recognized upon delivery to the patient. The Company receives payments from sales of its other products, primarily through third party payers, based on terms that generally are within 30 days of delivery of product to the patient.
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
49447000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
575000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
448248000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
3032000 usd
tvtx Number Of Phase One Half Clinical Trials
NumberOfPhaseOneHalfClinicalTrials
1 clinicaltrial
CY2023Q3 tvtx Number Of Phase3 Clinical Trials In Process
NumberOfPhase3ClinicalTrialsInProcess
2 clinicaltrial
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
7400000 usd
CY2023Q3 tvtx Number Of Direct To Patient Pharmacies Sold To
NumberOfDirectToPatientPharmaciesSoldTo
3 pharmacy
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
490399000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
388557000 usd
CY2023Q3 tvtx Debt Securities Availableforsale Amortized Cost Basis Current
DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent
213939000 usd
CY2023Q3 tvtx Debt Securities Available For Sale Unrealized Gain Current
DebtSecuritiesAvailableForSaleUnrealizedGainCurrent
10000 usd
CY2023Q3 tvtx Debt Securities Available For Sale Unrealized Loss Current
DebtSecuritiesAvailableForSaleUnrealizedLossCurrent
1321000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
212628000 usd
CY2023Q3 tvtx Debt Securities Availableforsale Amortized Cost Basis Noncurrent
DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent
279414000 usd
CY2023Q3 tvtx Debt Securities Available For Sale Unrealized Gain Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent
68000 usd
CY2023Q3 tvtx Debt Securities Available For Sale Unrealized Loss Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent
1711000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
277771000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
493353000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
78000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3032000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
490399000 usd
CY2022Q4 tvtx Debt Securities Availableforsale Amortized Cost Basis Current
DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent
287615000 usd
CY2022Q4 tvtx Debt Securities Available For Sale Unrealized Gain Current
DebtSecuritiesAvailableForSaleUnrealizedGainCurrent
2000 usd
CY2022Q4 tvtx Debt Securities Available For Sale Unrealized Loss Current
DebtSecuritiesAvailableForSaleUnrealizedLossCurrent
2091000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
285526000 usd
CY2022Q4 tvtx Debt Securities Availableforsale Amortized Cost Basis Noncurrent
DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent
103897000 usd
CY2022Q4 tvtx Debt Securities Available For Sale Unrealized Gain Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent
39000 usd
CY2022Q4 tvtx Debt Securities Available For Sale Unrealized Loss Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent
905000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
103031000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
391512000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
41000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2996000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
388557000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
284600000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
381300000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
329600000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
301100000 usd
CY2023Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
4100000 usd
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1900000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
398801000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
2457000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
248321000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1960000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
112420000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
1036000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
360741000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
2996000 usd
CY2023Q3 tvtx Debt Securities Available For Sale Unrealized Loss Position Amortized Cost
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCost
451300000 usd
CY2022Q4 tvtx Debt Securities Available For Sale Unrealized Loss Position Amortized Cost
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCost
363700000 usd
CY2023Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1582000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6501000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6673000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6889000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
7064000 usd
CY2023Q3 tvtx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
4781000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
33490000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4845000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
28645000 usd
CY2023Q3 tvtx Operating Lease Incentive Tenant Improvements
OperatingLeaseIncentiveTenantImprovements
4837000 usd
CY2023Q3 tvtx Straight Line Lease Expense In Excess Of Cash Payments
StraightLineLeaseExpenseInExcessOfCashPayments
5002000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18806000 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y10M24D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y8M12D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0648
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0648
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
3700000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
3700000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
144244000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
490399000 usd
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
634643000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
61688000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
388557000 usd
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
450245000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
195971000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
158783000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
89821000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
62463000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
106150000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
96320000 usd
CY2023Q3 us-gaap Goodwill
Goodwill
800000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
800000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10908000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5079000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
27358000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12825000 usd
CY2022Q1 tvtx Debt Instrument Repurchase Amount Including Accrued And Unpaid Interest
DebtInstrumentRepurchaseAmountIncludingAccruedAndUnpaidInterest
213800000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-7600000 usd
us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
3400000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
2800000 usd
us-gaap Interest Expense
InterestExpense
8500000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
2800000 usd
us-gaap Interest Expense
InterestExpense
8200000 usd
CY2023Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
26844000 usd
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
35267000 usd
CY2023Q3 tvtx Accrued Liabilities Researchand Development Current
AccruedLiabilitiesResearchandDevelopmentCurrent
26249000 usd
CY2022Q4 tvtx Accrued Liabilities Researchand Development Current
AccruedLiabilitiesResearchandDevelopmentCurrent
26070000 usd
CY2023Q3 tvtx Government Rebates Payable
GovernmentRebatesPayable
10385000 usd
CY2022Q4 tvtx Government Rebates Payable
GovernmentRebatesPayable
13486000 usd
CY2023Q3 tvtx Accrued Liabilities Selling Generaland Administrative Current
AccruedLiabilitiesSellingGeneralandAdministrativeCurrent
8707000 usd
CY2022Q4 tvtx Accrued Liabilities Selling Generaland Administrative Current
AccruedLiabilitiesSellingGeneralandAdministrativeCurrent
8791000 usd
CY2023Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
8002000 usd
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
7755000 usd
CY2023Q3 tvtx Accrued Liabilities Miscellaneous
AccruedLiabilitiesMiscellaneous
15525000 usd
CY2022Q4 tvtx Accrued Liabilities Miscellaneous
AccruedLiabilitiesMiscellaneous
4373000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
95712000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
95742000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76305603 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76305603 shares
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
150735000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
150735000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.97
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.97
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64033759 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-21226000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21226000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63604962 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63604962 shares
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-212659000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-212659000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.34
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25736005 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24043806 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25780850 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22751692 shares
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
22100000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7700000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
20.80
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11321000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8588000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
36102000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28846000 usd
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
16879000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2397000 usd
CY2023Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
972000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0 usd
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2922000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2126000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
20773000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
4523000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
14600000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16600000 usd
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
tvtx-20230930_cal.xml Edgar Link unprocessable
0001438533-23-000048-index-headers.html Edgar Link pending
0001438533-23-000048-index.html Edgar Link pending
0001438533-23-000048.txt Edgar Link pending
0001438533-23-000048-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
tvtx-20230930_lab.xml Edgar Link unprocessable
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tvtx-09302023x10qxex311.htm Edgar Link pending
tvtx-09302023x10qxex312.htm Edgar Link pending
tvtx-09302023x10qxex321.htm Edgar Link pending
tvtx-09302023x10qxex322.htm Edgar Link pending
tvtx-20230930.htm Edgar Link pending
tvtx-20230930.xsd Edgar Link pending
tvtx-20230930_g1.jpg Edgar Link pending
tvtx-20230930_def.xml Edgar Link unprocessable
tvtx-20230930_htm.xml Edgar Link completed
tvtx-20230930_pre.xml Edgar Link unprocessable